VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XLO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XLOXilio Therapeutics, Inc.
$7.54$50M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. XLO
  4. Financial Ratios

Xilio Therapeutics, Inc. (XLO) Financial Ratios

Latest Ratios: P/E Ratio -13.1x · EV/EBITDA N/A · ROE -132.5%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

XLO Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$50M$75M$51M$15M$74M$90M——
Enterprise Value$-80408689$-55679840$4M$-17077200$-26745380$-87615976——
P/E Ratio →-13.07———————
P/S Ratio0.911.718.05—————
P/B Ratio1.812.122.900.410.700.48——
P/FCF————————
P/OCF————————

P/E links to full P/E history page with 30-year chart

XLO EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—-1.270.62—————
EV / EBITDA————————
EV / EBIT————————
EV / FCF————————

XLO Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin96.5%96.5%100.0%—————
Operating Margin-95.9%-95.9%-954.9%—————
Net Profit Margin-80.1%-80.1%-918.0%—————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-132.5%-132.5%-214.0%-107.3%-60.6%-84.2%-332.4%-45.0%
ROA-31.0%-31.0%-88.2%-76.4%-48.9%-58.8%-111.5%-27.6%
ROIC———-1207.8%-1004.5%-2056.0%-1446.3%—
ROCE-59.0%-59.0%-136.5%-97.1%-54.5%-67.3%-152.2%-33.1%

XLO Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.200.200.460.340.190.11—0.48
Debt / EBITDA————————
Net Debt / Equity—-3.70-2.68-0.87-0.95-0.96—-0.78
Net Debt / EBITDA————————
Debt / FCF————————
Interest Coverage——-596.45——-125.33-91.03—

Net cash position: cash ($138M) exceeds total debt ($7M)

XLO Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio2.582.582.213.025.8915.850.939.81
Quick Ratio2.582.582.213.025.8915.850.939.81
Cash Ratio2.442.442.032.805.7015.500.879.38
Asset Turnover—0.280.09—————
Inventory Turnover————————
Days Sales Outstanding—41.70——————

XLO Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield————————
FCF Yield————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$8M$4M$2M$2M$400451$37413$29236

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Cash burn against lumpy collaboration revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Negative Earnings Leave Sales Multiple Anchoring Valuation

Based on the reported trailing figures, XLO trades at a P/E of -2.06 and a P/S of 3.82 with a P/B of 20.43, leaving the sales multiple as the only meaningful earnings-independent anchor for a company without positive profits.

With trailing net income negative, the P/E ratio carries no interpretive weight and the sales multiple becomes the primary reference point, though a 3.82 P/S is hard to justify against revenue that swung from $2.9M to $19.1M across the period. The P/B of 20.43 compared with a retained deficit of -$434.7M suggests the market is pricing pipeline value rather than book equity, and investors should monitor whether the valuation depends on milestone recognition that may not repeat. Peer multiples are not comparable on earnings for most of the group, since NKTX, IMVT, and CLDX also carry negative P/E, so the comparison rests on P/B and pipeline assumptions that the supplied data cannot verify.

Minimal Debt Keeps Leverage Largely Irrelevant

As reported in the balance sheet, XLO's D/E ratio sits near 0.09 in 2026Q2 with total debt of $6.3M, while interest coverage and EBITDA-based leverage are unavailable because operating earnings are negative.

The debt load has drifted down from $8.9M over ten quarters, and at this scale it does not constrain the company's financing position on its own. Interest coverage and Debt/EBITDA cannot be meaningfully computed given negative operating income, so the data does not allow a judgment on debt service comfort. The more relevant risk is equity-funded dilution and milestone-dependent financing rather than covenant or refinancing pressure, which warrants monitoring given the scale of ongoing operating losses.

Cash Buffer Covers Liabilities Substantially

Based on reported figures, XLO's current ratio of 4.25 in 2026Q2 and cash of $136.0M against $82.0M of total liabilities suggest a substantial near-term buffer, though deferred revenue of $35.3M may tie up part of that cash.

A current ratio that climbed from 1.67 to 4.25 over the period suggests the balance sheet has been rebuilt through capital and collaboration inflows, not through operating profit. Because quick and current ratios are identical here and inventory is absent for a research-stage model, the ratio is a clean read on cash versus obligations. Investors should note that deferred revenue obligations may reduce the economic freedom of the cash balance, and a stress case that assumes continued quarterly burn would deplete this buffer faster than the headline ratio implies.

Returns Oscillate Without Compounding Pattern

As reported in quarterly data, XLO's ROE moved from -94% to 76% and back to -18% across recent quarters, with ROIC reported only once at -6.1%, so the return trend reflects one-off items rather than durable capital efficiency.

The swing in ROE is driven by net income volatility from collaboration revenue and non-operating items, not by an improving operating base, since operating margin remained negative in most quarters. With ROIC data sparse, a multi-year compounding view cannot be established, and investors should treat the positive ROE quarter as a timing artifact rather than evidence of sustained returns. Relative to TGTX, which reports ROIC of 16.4%, XLO's economics remain far from proven at the operating level.

Quick Ratio Obscures Cash Burn Dependence

The current ratio is most commonly used as a comfort metric for biotech balance sheets, but for XLO it hides that 4.25 coverage reflects episodic inflows against persistent free cash outflow.

A healthy current ratio says nothing about the rate at which cash is consumed, and a company with negative free cash flow in most quarters may see that coverage erode quickly. The more useful measure is cash runway, calculated as cash divided by average quarterly operating burn, which the supplied data supports directionally but does not state explicitly. Investors should monitor how much of the $136.0M cash position is restricted by deferred revenue obligations before treating the liquidity ratio as a measure of financial strength.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open XLO Terminal

XLO Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

XLO — Frequently Asked Questions

Quick answers to the most common questions about buying XLO stock.

What is Xilio Therapeutics, Inc.'s P/E ratio?

Xilio Therapeutics, Inc.'s current P/E ratio is -13.1x. This places it at the 50th percentile of its historical range.

What is Xilio Therapeutics, Inc.'s ROE?

Xilio Therapeutics, Inc.'s return on equity (ROE) is -132.5%. The historical average is -139.4%.

Is XLO stock overvalued?

Based on historical data, Xilio Therapeutics, Inc. is trading at a P/E of -13.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Xilio Therapeutics, Inc.'s profit margins?

Xilio Therapeutics, Inc. has 96.5% gross margin and -95.9% operating margin.